EVOMYO
Live / Applied — Third extension granted (statement of use) (as of 12 Jan 2026)
What this means for you
Not registered yet, but its 13 Jun 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98040253
- Mark type
- Stylized text
- Filed
- 13 Jun 2023
- Published for opposition
- 21 May 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs being pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 13 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Jan 2026 — SOU EXTENSION 3 GRANTED
- 12 Jan 2026 — SOU EXTENSION 3 FILED
- 12 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 10 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jul 2025 — SOU EXTENSION 2 GRANTED
- 09 Jul 2025 — SOU EXTENSION 2 FILED
- 09 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Jan 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Jan 2025 — SOU EXTENSION 1 GRANTED
- 13 Jan 2025 — SOU EXTENSION 1 FILED
- 13 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 16 Jul 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 21 May 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 21 May 2024 — PUBLISHED FOR OPPOSITION